全球糖尿病药物市场概览  

Report on Global Sales of Antidiabetic Drugs

作　　者：李子艳 王春丽 黄瑶庆 高柳滨 LI Ziyan;WANG Chunli;HUANG Yaoqing;GAO Liubin(Intelligence Research Department,Information Center,Shanghai Institute of Materia Medica Chinese Academy of Sciences,Shanghai 201203,China)

机构地区：[1]中国科学院上海药物研究所信息中心,上海201203

出　　处：《药学进展》2021年第10期793-800,共8页Progress in Pharmaceutical Sciences

基　　金：中国科学院战略性先导科技专项(No.XDA12050201)。

摘　　要：当前,糖尿病药物市场已经成为仅次于肿瘤用药的第二大药品市场。在全球市场上,糖尿病药物种类繁多,除了占据主导地位的胰岛素和传统的α-葡萄糖苷酶抑制剂、磺酰脲类、双胍类和格列奈类等降糖药之外,胰高血糖素样肽-1(GLP-1)、二肽基肽酶Ⅳ(DPPⅣ)和钠-葡萄糖协同转运蛋白-2(SGLT-2)等新靶点糖尿病药物近年来在临床上也得到了广泛的应用,并成为了市场热点。综述近5年全球及中国糖尿病药物市场概况,重点介绍糖尿病新药GLP-1受体激动剂、DPPⅣ抑制剂、SGLT-2抑制剂等的市场态势,以期为我国糖尿病新药研发布局提供参考。Currently, the antidiabetic drug market has become the second largest drug market only to that of anti-tumor drugs. There are many types of antidiabetic drugs on the market. In addition to the dominant insulin and its analogues and traditional drugs such as α-glucosidase inhibitors, sulfonylureas, biguanides and glinides, new target antidiabetic drugs such as GLP-1 agonists, DPP Ⅳ inhibitors and SGLT-2 inhibitors have also been widely used clinically in recent years and have become a hot spot on the market. This paper summarizes the global sales of antidiabetic drugs in the past 5 years, and highlights the market trend of GLP-1 receptor agonists, DPP Ⅳinhibitors and SGLT-2 inhibitors, in order to provide reference for antidiabetic drug innovation in China.

关 键 词：糖尿病药物 药物市场 GLP-1受体激动剂 DPPⅣ抑制剂 SGLT-2抑制剂 

分 类 号：R977.15[医药卫生—药品]